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Abstract
Background: Monocytes play an important role in innate immunity and atherosclerosis. A
disturbed secretion of cytokines in lipopolysaccharide (LPS) activated monocytes from type 1
diabetes (T1D) patients has been described and may contribute to the impaired inflammatory
response in these individuals. In the present study the influence of LPS on five different proteins
with a function in immunity and atherosclerosis was analyzed in monocytes from controls and T1D
patients.
Methods: Monocytes were isolated from controls and T1D patients and the LPS-stimulated
increase of IL-6, CXCL8, monocyte chemotactic protein 1 (CCL2, MCP-1) and superoxide
dismutase (SOD 2), as well as the LPS-mediated decrease of apolipoprotein E (Apo E) in primary
human monocytes from controls and T1D patients was determined.
Results: CCL2 and IL-6 secretion in response to LPS was found significantly reduced in monocytes
from T1D patients when compared to controls whereas basal CCL2 release was similar in control
and T1D cells. In contrast, CXCL8 and apolipoprotein E secretion and SOD 2 expression upon LPS
stimulation is similar from T1D and control monocytes.
Conclusion: These data indicate that LPS-mediated protein expression is only partly disturbed in
monocytes from T1D patients. Reduced secretion of IL-6 and CCL2 in activated monocytes of
these patients may contribute to an impaired inflammatory response and vascular disease.
Background
Type 1 diabetes mellitus (T1D) is a complex disease with
genetic and environmental factors involved in its etiology
[1,2]. T1D carries a substantial risk of morbidity and early
mortality due to its complications, which affect the
macro- and microvasculature [3]. An impaired production
of cytokines by monocytes and macrophages of these
patients has been associated with the pathophysiology of
T1D. Monocytes play an important role in the innate
immune response and vascular complications and an
abnormal cytokine release may contribute to premature
atherosclerosis and reduced immune function in T1D
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response of T1D monocytes to endotoxin shown by an
altered cytokine secretion [6]. In one study purified
monocytes of T1D patients treated with LPS had an ele-
vated release of IL-6 and IL-10 whereas TNF was not
altered [7]. Other reports, however, describe reduced IL-6
and IL-1 levels [8] or diminished IL-6 and IL-10 release of
endotoxin activated T1D monocytes [9]. The non-obese
diabetic (NOD) mouse is a widely used animal model to
study T1D and peritoneal macrophages activated with LPS
have reduced IL-1 and TNF secretion whereas IL-6 and IL-
10 were not altered [10]. Leukocytes of these mice have a
severely impaired migration towards sites of inflamma-
tion that might be partly explained by a disturbed
cytokine profile in these animals [11].
Cytokines and chemokines are the main group of genes
induced by LPS [12]. Chemokines are key signal mole-
cules that attract cells of the immune system to the site of
inflammation and also have a prominent role in the for-
mation of early atherosclerotic lesions. The most thor-
oughly characterized CC chemokine is CCL2 (MCP-1)
and several studies provide evidence that CCL2 is the
main chemokine involved in the recruitment of mono-
cytes from blood into early lesions. However, NOD exsu-
date macrophages and monocytes from T1D patients
display a severely reduced migration towards CCL2
[11,13]. CXCL8 (IL-8), a CXC chemokine is also induced
by LPS, stimulates the adhesion of monocytes to endothe-
lial cells and has also been linked to the development of
early atherosclerosis [14].
Manganese superoxid dismutase (SOD 2) is also upregu-
lated by LPS and protects the cell against damage by
superoxide radicals [15]. Decreased activity of this
enzyme has been associated with the pathogenesis of T1D
[16] and an enhanced release of superoxide has been
reported in neutrophils from poorly controlled T1D
patients [17].
Apolipoprotein E (Apo E) inhibits local inflammatory
responses [18] and enhances the clearance of cellular lip-
ids [19]. Apo E release is suppressed in LPS-activated
monocytes and this may contribute to an enhanced secre-
tion of type I cytokines and lipid accumulation in acti-
vated macrophages [20].
LPS may be linked to vascular disease and low levels of cir-
culating endotoxin in men and rabbits promote the devel-
opment of atherosclerosis [21,22]. Deficiency of the LPS
receptor TLR4 or MyD88 involved in LPS-signaling
decrease plaque size and macrophage infiltration [23,24].
These recent findings indicate that an altered inflamma-
tory response of T1D monocytes may not only affect
innate immunity but in addition premature cardiovascu-
lar disease in these patients. Therefore we investigated the
response of T1D monocytes and control cells to LPS as an
proinflammatory and proatherogenic mediator. The
secretion of the multifunctional cytokine IL-6 [25] and the
chemokines CCL2 and CXCL8, that attract cells of the
immune system like monocytes and are released by these
cells, was investigated [26]. The abundance of Apo E,
which mediates lipid efflux from monocytes and exerts
immunsuppressive effects [27] and the expression of the
radical scavenging enzyme SOD 2 were determined [28].
Methods
Patients and controls
Monocytes were purified from the blood of 10 female
controls and 10 female T1D patients. The median age of
the controls was 24 years (range 24 – 43) and of the
patients 36.5 years (range 18 – 46). The mean body mass
index (BMI) of controls was 20.6 kg/m2 (range 17.5 –
22.3) and of the T1D patients 22.3 kg/m2 (range 19.5 –
31). Only patients with a known history of T1D and an
established therapy with intensive insulin treatment were
recruited for the study. The median duration of diabetes
was 13.5 years (range 7 – 34). The mean HbA1c was 7.2
% (range 5.7 – 9.5). Patients had no infectious disease
within two weeks before blood was drawn. C-reactive pro-
tein was determined by an ELISA from Anogen (Ontario,
Canada) in the plasma and was 1.94 mg/l (range 0.5 – 5)
in controls and 1.1 mg/l (range 0.7 – 1.6) in T1D. All
women gave informed consent and the study was
approved by the local Medical Ethical Committee.
Reagents
Macrophage SFM medium was from Gibco BRL (Karl-
sruhe, Germany). Recombinant M-CSF and CXCL8 ELISA
were from R&D Systems (Wiesbaden-Nordenstadt, Ger-
many), IL-6 ELISA was from Pierce Biotechnology (Rock-
ford, Illinois), and CCL2 ELISA was obtained from
Amersham Biosciences (Freiburg, Germany). E. coli
derived recombinant human proteins were used as stand-
ard for the IL-6, CXCL8 and CCL2 ELISAs. SOD 2 anti-
body was from Abcam (Cambridge, UK) and Apo E
antibody was from Chemicon (Hampshire, U.K.). Vacu-
tainer CPT were from Becton Dickinson (Franklin Lakes,
NJ). LPS, E. coli serotype 055:B5 was ordered from Sigma
Chemicals (Deisenhofen, Germany). Apo E ELISA was
from MoBiTec (Goettingen, Germany) and the calibrator
is derived from human serum.
Isolation and culture of primary blood monocytes
Peripheral blood leukocytes were isolated from 16 ml of
whole blood by Vacutainer CPT and monocytes were fur-
ther purified by magnetic separation with CD14 beads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of
the isolated monocytes was determined by flow cytomet-
ric analysis and was more than 98%. 500,000 monocytesPage 2 of 8
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wells plates with 50 ng/ml M-CSF for 24 h. Subsequently
the medium was replaced. Monocytes were either culti-
vated in 500 µl macrophage SFM medium with M-CSF or
in the identical media supplemented with 1 µg/ml LPS.
Supernatants and cells were collected 24 h later and used
for ELISA or immunoblotting.
SDS-PAGE and immunoblotting
The cells were solubilized in RIPA buffer. 8 µg of protein
were separated by SDS-polyacrylamide gel electrophoresis
and were transferred to PVDF membranes (Bio-Rad, Ger-
many). Incubations with antibodies were performed in
1% BSA in PBS, 0.1% Tween overnight. Detection of the
immune complexes was carried out with the ECL Western
blot detection system (Amersham Pharmacia, Deisen-
hofen, Germany).
Statistics
Data are represented as Box Plots indicating the median,
the upper and lower quartile, the largest and the lowest
value in the data set. In the manuscript data are given as
median value and the range of the values. Statistical differ-
ences were analyzed by two tailed Mann-Whitney U Test
and a value of P < 0.05 was regarded as statistically signif-
icant.
Results
LPS-induced IL-6 secretion in monocytes from controls and 
T1D patients
IL-6 was determined in the supernatants of monocytes
treated with LPS or cultured in medium alone by ELISA.
IL-6 was not detected in cells from controls and mono-
cytes from T1D patients not treated with LPS indicating
that only low amounts of IL-6 are released (not shown).
This demonstrates that non-activated monocytes were
used for the study. IL-6 was markedly elevated in the
supernatants of LPS incubated cells. The median of LPS
induced secretion in monocytes from controls was 9,469
pg/ml (range 1,503–16,000) and in monocytes isolated
from T1D patients 2,742 pg/ml (range 775–7,431) (Fig-
ure 1A) indicating a significant reduced IL-6 release in
monocytes from T1D patients (p = 0.001).
Basal and LPS-induced CCL2 secretion in monocytes from 
controls and T1D patients
The supernatants described above were also used to meas-
ure CCL2. CCL2 is constitutively secreted by non-stimu-
lated monocytes and was 543 pg/ml (range 369–1,693) in
controls and 461 pg/ml (range 202–1,604) in monocytes
from T1D patients (Figure 1B) and therefore is similar in
unstimulated monocytes isolated from controls or T1D
patients. In LPS-treated cells, CCL2 secretion is strongly
induced. CCL2 secreted from control monocytes was
39,882 pg/ml (range 9,698–74,597) and from T1D 9,961
pg/ml (range 4,509–22,980). LPS-induced release of
CCL2 is lower in monocytes from T1D patients when
compared to controls and this difference is statistically sig-
nificant (p = 0.00014) (Figure 1C).
Basal and LPS-induced CXCL8 secretion in monocytes 
from controls and T1D patients
Furthermore CXCL8 was determined in the supernatants
by ELISA. CXCL8 is already expressed in non-stimulated
monocytes and was 19,252 pg/ml (range 8,002–40,221)
in controls and 24,126 (1,302–42,504) in monocytes
from T1D patients indicating a similar release of this
chemokine (p = 0.47) (Figure 2A). CXCL8 in LPS-acti-
vated monocytes from controls was 659,000 pg/ml (range
257,000 – 1,710,000) and 890,000 pg/ml (range
185,000–1,150,000) in T1D monocytes (p = 0.26) (Figure
2B).
Apo E release in LPS-stimulated cells
Apo E secretion is suppressed by LPS and this was con-
firmed in our study by immunoblot using cell lysates from
control and T1D monocytes (Figure 2C). Apo E release
was measured by ELISA in LPS-activated monocytes and
was 3,017 ng/ml (range 2,800–3,100) from controls and
2,961 ng/ml (range 2,957–3,200) from T1D monocytes
and therefore was similar in LPS-activated monocytes
from controls and T1D patients (Figure 2D).
LPS-induced SOD 2 in monocytes from controls and T1D 
patients
SOD 2 was analyzed by immunoblot in monocytes iso-
lated from six controls and six T1D patients. With the
exception of cells isolated from one control individual
(C2 in figure 3), the expression of SOD 2 was induced by
LPS. A representative immunoblot is shown in Figure 3.
Quantification of the immunoblots using the OptiQuant
software revealed that SOD 2 is 2.0 ± 1.4 fold induced in
controls and 3.2 + 1.8 fold induced in T1D cells indicating
a similar upregulation of SOD 2 by LPS in control and
patients cells.
Discussion
When compared to monocytes isolated from controls,
T1D cells show a significantly lower secretion of IL-6 and
CCL2 upon LPS-stimulation. The reduced IL-6 release
from activated monocytes is a confirmatory finding and
has already been published by two studies ([8,9]. In con-
trast, Spatz et al. describe an elevated IL-6 in T1D cells [7].
The reason for this discrepancy is so far unclear but nei-
ther duration of diabetes nor gender of the patients may
explain this different findings. Increased serum levels of
IL-6 have been found in patients with stroke or type 2 dia-
betes mellitus and IL-6 is suggested to increase the risk of
coronary artery disease [29,30]. This may indicate that
reduced IL-6 release of LPS-activated T1D monocytes isPage 3 of 8
(page number not for citation purposes)
Cardiovascular Diabetology 2006, 5:5 http://www.cardiab.com/content/5/1/5
Page 4 of 8
(page number not for citation purposes)
LPS-stimulated IL-6 and CCL2 secretion of T1D and control monocytesFigure 1
LPS-stimulated IL-6 and CCL2 secretion of T1D and control monocytes. Monocytes from 10 controls and 10 T1D 
patients were cultivated as described in the text. IL-6 (A) and CCL2 (C) were determined in the supernatant of cells treated 
with 1 µg/ml LPS for 24 h. CCL2 was also determined in unstimulated monocytes (B). Outliers are indicated by the dots.
Cardiovascular Diabetology 2006, 5:5 http://www.cardiab.com/content/5/1/5
Page 5 of 8
(page number not for citation purposes)
LPS-mediated CXCL8 and Apo E in T1D and control monocytesFigur  2
LPS-mediated CXCL8 and Apo E in T1D and control monocytes. Monocytes from controls and T1D patients were 
cultivated with or without LPS for 24 h. CXCL8 was determined in non-activated monocytes of controls and T1D patients (A) 
and LPS-activated cells (B). Intracellular Apo E was analyzed by immunoblot and the result for monocytes from control 1 and 2 
(C1, C2) and T1D patient 1 and 2 (D1, D2) is shown (C). Apo E was determined in the supernatants of 10 control and 10 T1D 
monocytes treated with 1 µg/ml LPS for 24 h. Outliers are indicated by the dots (D).
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ever, impaired IL-6 secretion may contribute to an ineffec-
tive innate immune response and higher incidence and
duration of infections [31] and this may secondary pro-
mote atherogenesis.
Diminished secretion of CCL2 by LPS-stimulated T1D
cells has not been described so far. This chemokine is a
potent agonist for monocytes and T-cells. Levels of CCL2
are increased early in the course of plaque formation and
lead to increased monocyte migration into the atheroscle-
rotic lesion [26]. Monocytes migrate into the intima due
to a CCL2 concentration gradient that is formed by
endothelial cells and monocytes [32]. Lower expression of
CCL2 by activated T1D cells may increase this gradient
and enhance migration of monocytes to the endothelium.
Furthermore CCL2 is decreased in the serum T1D patients
[33] and diminished secretion of CCL2 by activated
monocytes may contribute to reduced serum levels.
Depletion of CCL2 was demonstrated to alter the expres-
sion of at least nine additional genes [34] showing that
the chemokine network is highly sensitive to any altera-
tions. The chemokine CXCL8 also activates monocytes
and may recruit these cells to the endothelium. CXCL8
was so far not analyzed in T1D monocytes but was found
similar abundant in the serum of T1D patients and con-
trols [35]. This chemokine is secreted by various cells and
here we describe that CXCL8 release is similar in non-
stimulated and LPS-activated monocytes from T1D
patients when compared to controls.
SOD 2 converts superoxide to oxygen plus hydrogen per-
oxide and serves as the primary defense against mitochon-
drial superoxide [15]. Enhanced oxidative stress may
promote inflammation and atherosclerosis [36]. Further-
more, superoxides potentiate LPS-stimulated production
of IL-6 [37]. However, LPS-induced SOD 2 expression was
similar in monocytes of T1D cells and controls indicating
that an altered regulation of SOD 2, that may be associ-
ated with elevated or reduced superoxide release, does not
explain altered inflammatory response in T1D nor prema-
ture cardiovascular disease.
Apo E is important for lipid efflux of monocytic cells and
Apo E deficiency in mice is associated with atherosclero-
sis. Loss of Apo E results in an impaired clearance of apop-
totic cell remnants by phagocytes and leads to systemic
proinflammatory conditions [27]. Apo E synthesis and
secretion is suppressed by LPS in monocytes [20,38] and
was found similar abundant in endotoxin treated mono-
cytes from controls and T1D patients. Apo E protects
monocytes from lipid accumulation [19] and furthermore
reduces the release of type I inflammatory cytokines like
IL-6 in LPS-treated mice [18]. Because Apo E release is
similar in LPS-activated monocytes from controls and
T1D patients, an altered Apo E secretion in T1D cells can
be ruled out to explain reduced IL-6 release. Deficiency of
macrophage Apo E is strongly associated with atherogen-
esis in mice [19] but may not be a factor in premature car-
diovascular disease in T1D.
SOD 2 in LPS-stimulated T1D and control monocytesFigure 3
SOD 2 in LPS-stimulated T1D and control monocytes. Monocytes from four different controls (C1 to C4) and four dif-
ferent T1D patients (D1 to D4) were cultivated with or without LPS for 24 h. SOD 2 was determined by immunoblot and a 
representative immunoblot from control 1 and 2 (C1, C2) and T1D patient 1 and 2 (D1, D2) is shown.Page 6 of 8
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pathways are only partly impaired in T1D monocytes.
Though it is clear that the expression of the proteins inves-
tigated in the present study is regulated by LPS, different
intracellular signal transduction pathways are most likely
involved. Whereas induction of IL-6 and CCL2 depends
on the mitogen-activated protein kinases ERK1/2 and p38
[39], upregulation of CXCL8 is mediated by ERK1/2 but
not p38 [40] and SOD 2 is upregulated independent of
MAPK [15]. LPS-mediated reduction of Apo E may be
facilitated by an autocrine, TNF-dependent mechanism
[20]. However, LPS-signaling is highly complex and vari-
ous proteins and transcription factors are involved until
an altered protein expression is achieved [38]. Therefore
additional studies are needed to identify the pathways
that are affected in T1D monocytes.
The T1D patients in our study are relatively young with so
far no secondary complications of T1D. The median
HbA1c value of 7.2% indicates that the diabetes is well
controlled. Therefore, the observed diminished inflam-
matory response of the T1D monocytes is most likely not
a secondary effect of T1D but may be an intrinsic property
of the cells.
Conclusion
Taken together, the present study demonstrates a dimin-
shed release of IL-6 and CCL2 from LPS activated T1D
monocytes indicating an impaired primary immune
response that subsequently promotes atherosclerosis in
these patients.
Abbreviations
Apolipoprotein E (Apo E), extracellular signal-regulated
protein kinase (ERK), interleukin-6 (IL-6), interleukin-8
(IL-8; CXCL8), lipopolysaccharide (LPS), macrophage
colony stimulating factor (M-CSF), mitogen-activated
protein kinase (MAPK), monocyte chemotactic protein 1
(CCL2, MCP-1), myeloid differentiation primary
response gene (MyD88), non-obese diabetic (NOD),
superoxide dismutase (SOD 2), toll-like receptor 4
(TLR4), tumor necrosis factor (TNF), type 1 diabetes
(T1D).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
GW collected the patients and control samples and carried
out immunoassays; MN carried out immunoassays; AS
participated in the design of the study; AK, JW and SA car-
ried out immunoassays, JS is the head of the department
and provided the required resources for research and was
involved in fruitful discussions and preparation of the
manuscript; CB conceived of the study, and participated
in its design and coordination.
Acknowledgements
The technical assistance of Kerstin Winkler and Natalie Smolnikow is 
greatly appreciated.
References
1. Campbell IL, Kay TW, Oxbrow L, Harrison LC: Essential role for
interferon-gamma and interleukin-6 in autoimmune insulin-
dependent diabetes in NOD/Wehi mice.  J Clin Invest 1991,
87:739-742.
2. Alberti KG, Zimmet PZ: Definition, diagnosis and classification
of diabetes mellitus and its complications. Part 1: diagnosis
and classification of diabetes mellitus provisional report of a
WHO consultation.  Diabet Med 1998, 15:539-553.
3. Jensen T, Deckert T: Diabetic retinopathy, nephropathy and
neuropathy. Generalized vascular damage in insulin-depend-
ent diabetic patients.  Horm Metab Res Suppl 1992, 26:68-70.
4. Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC: Asso-
ciation of HbA1c with prevalent cardiovascular disease in
the original cohort of the Framingham Heart Study.  Diabetes
1992, 41:202-208.
5. Patterson JE, Andriole VT: Bacterial urinary tract infections in
diabetes.  Infect Dis Clin North Am 1997, 11:735-750.
6. Geerlings SE, Hoepelman AI: Immune dysfunction in patients
with diabetes mellitus (DM).  FEMS Immunol Med Microbiol 1999,
26:259-265.
7. Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, Mayr WR, Schern-
thaner G, Eibl MM: Impaired primary immune response in
type-1 diabetes. Functional impairment at the level of APCs
and T-cells.  Cell Immunol 2003, 221:15-26.
8. Ohno Y, Aoki N, Nishimura A: In vitro production of interleukin-
1, interleukin-6, and tumor necrosis factor-alpha in insulin-
dependent diabetes mellitus.  J Clin Endocrinol Metab 1993,
77:1072-1077.
9. Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP,
Hoepelman AI: Cytokine secretion is impaired in women with
diabetes mellitus.  Eur J Clin Invest 2000, 30:995-1001.
10. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI: Aberrant
macrophage cytokine production is a conserved feature
among autoimmune-prone mouse strains: elevated inter-
leukin (IL)-12 and an imbalance in tumor necrosis factor-
alpha and IL-10 define a unique cytokine profile in macro-
phages from young nonobese diabetic mice.  Diabetes 2000,
49:1106-1115.
11. Bouma G, Nikolic T, Coppens JM, van Helden-Meeuwsen CG, Leenen
PJ, Drexhage HA, Sozzani S, Versnel MA: NOD mice have a
severely impaired ability to recruit leukocytes into sites of
inflammation.  Eur J Immunol 2005, 35:225-235.
12. Hashimoto S, Morohoshi K, Suzuki T, Matsushima K: Lipopolysac-
charide-inducible gene expression profile in human mono-
cytes.  Scand J Infect Dis 2003, 35:619-627.
13. Bouma G, Coppens JM, Lam-Tse WK, Luini W, Sintnicolaas K, Lever-
ing WH, Sozzani S, Drexhage HA, Versnel MA: An increased
MRP8/14 expression and adhesion, but a decreased migra-
tion towards proinflammatory chemokines of type 1 diabe-
tes monocytes.  Clin Exp Immunol 2005, 141:509-517.
14. Charo IF, Ransohoff RM: The many roles of chemokines and
chemokine receptors in inflammation.  N Engl J Med 2006,
354:610-621.
15. Tian L, White JE, Lin HY, Haran VS, Sacco J, Chikkappa G, Davis FB,
Davis PJ, Tsan MF: Induction of Mn SOD in human monocytes
without inflammatory cytokine production by a mutant
endotoxin.  Am J Physiol 1998, 275:C740-7.
16. Pociot F, Lorenzen T, Nerup J: A manganese superoxide dis-
mutase (SOD2) gene polymorphism in insulin-dependent
diabetes mellitus.  Dis Markers 1993, 11:267-274.
17. Karima M, Kantarci A, Ohira T, Hasturk H, Jones VL, Nam BH, Mala-
banan A, Trackman PC, Badwey JA, Van Dyke TE: Enhanced super-
oxide release and elevated protein kinase C activity in
neutrophils from diabetic patients: association with perio-
dontitis.  J Leukoc Biol 2005, 78:862-870.Page 7 of 8
(page number not for citation purposes)
Cardiovascular Diabetology 2006, 5:5 http://www.cardiab.com/content/5/1/5Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
18. Ali K, Middleton M, Pure E, Rader DJ: Apolipoprotein E sup-
presses the type I inflammatory response in vivo.  Circ Res
2005, 97:922-927.
19. Larkin L, Khachigian LM, Jessup W: Regulation of apolipoprotein
E production in macrophages (review).  Int J Mol Med 2000,
6:253-258.
20. Zuckerman SH, O'Neal L: Endotoxin and GM-CSF-mediated
down-regulation of macrophage apo E secretion is inhibited
by a TNF-specific monoclonal antibody.  J Leukoc Biol 1994,
55:743-748.
21. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich
M, Reifenberg K, Bhakdi S: Immunopathogenesis of atheroscle-
rosis: endotoxin accelerates atherosclerosis in rabbits on
hypercholesterolemic diet.  Circulation 2001, 104:914-920.
22. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G,
Oberhollenzer F, Willeit J: Association of endotoxemia with
carotid atherosclerosis and cardiovascular disease: prospec-
tive results from the Bruneck Study.  J Am Coll Cardiol 1999,
34:1975-1981.
23. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee
MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW:
Reduced atherosclerosis in MyD88-null mice links elevated
serum cholesterol levels to activation of innate immunity
signaling pathways.  Nat Med 2004, 10:416-421.
24. Ishida BY, Blanche PJ, Nichols AV, Yashar M, Paigen B: Effects of
atherogenic diet consumption on lipoproteins in mouse
strains C57BL/6 and C3H.  J Lipid Res 1991, 32:559-568.
25. Lobbes MB, Lutgens E, Heeneman S, Cleutjens KB, Kooi ME, van
Engelshoven JM, Daemen MJ, Nelemans PJ: Is there more than C-
reactive protein and fibrinogen? The prognostic value of sol-
uble CD40 ligand, interleukin-6 and oxidized low-density
lipoprotein with respect to coronary and cerebral vascular
disease.  Atherosclerosis 2005.
26. Charo IF, Taubman MB: Chemokines in the pathogenesis of vas-
cular disease.  Circ Res 2004, 95:858-866.
27. Grainger DJ, Reckless J, McKilligin E: Apolipoprotein E modulates
clearance of apoptotic bodies in vitro and in vivo, resulting in
a systemic proinflammatory state in apolipoprotein E-defi-
cient mice.  J Immunol 2004, 173:6366-6375.
28. Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, Utsumi K:
Mitochondrial generation of reactive oxygen species and its
role in aerobic life.  Curr Med Chem 2003, 10:2495-2505.
29. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concen-
tration of interleukin-6 and the risk of future myocardial inf-
arction among apparently healthy men.  Circulation 2000,
101:1767-1772.
30. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Ran-
tanen T, Pyorala K: C-reactive protein, fibrinogen, interleukin-
6 and tumour necrosis factor-alpha in the prognostic classifi-
cation of unstable angina pectoris.  Ann Med 2001, 33:37-47.
31. Liberatore Rdel RJ, Barbosa SF, Alkimin MG, Bellinati-Pires R, Florido
MP, Isaac L, Kirschfink M, Grumach AS: Is immunity in diabetic
patients influencing the susceptibility to infections? Immu-
noglobulins, complement and phagocytic function in chil-
dren and adolescents with type 1 diabetes mellitus.  Pediatr
Diabetes 2005, 6:206-212.
32. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS: Cytokine-activated
human endothelial cells synthesize and secrete a monocyte
chemoattractant, MCP-1/JE.  Am J Pathol 1990, 136:1229-1233.
33. Ferreira AM, Rollins BJ, Faunce DE, Burns AL, Zhu X, Dipietro LA:
The effect of MCP-1 depletion on chemokine and chemok-
ine-related gene expression: evidence for a complex net-
work in acute inflammation.  Cytokine 2005, 30:64-71.
34. Puddu GM, Cravero E, Arnone G, Muscari A, Puddu P: Molecular
aspects of atherogenesis: new insights and unsolved ques-
tions.  J Biomed Sci 2005, 12:839-853.
35. Ndengele MM, Muscoli C, Wang ZQ, Doyle TM, Matuschak GM,
Salvemini D: Superoxide potentiates NF-kappaB activation
and modulates endotoxin-induced cytokine production in
alveolar macrophages.  Shock 2005, 23:186-193.
36. Werb Z, Chin JR: Endotoxin suppresses expression of apopro-
tein E by mouse macrophages in vivo and in culture. A bio-
chemical and genetic study.  J Biol Chem 1983, 258:10642-10648.
37. Guha M, Mackman N: LPS induction of gene expression in
human monocytes.  Cell Signal 2001, 13:85-94.
38. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurn-
berg SA, Magolda RL, Trzaskos JM: Inhibition of MAP kinase
kinase prevents cytokine and prostaglandin E2 production in
lipopolysaccharide-stimulated monocytes.  J Immunol 1998,
161:5681-5686.
39. Guha M, Mackman N: LPS induction of gene expression in
human monocytes.  Cell Signal 2001, 13:85-94.
40. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurn-
berg SA, Magolda RL, Trzaskos JM: Inhibition of MAP kinase
kinase prevents cytokine and prostaglandin E2 production in
lipopolysaccharide-stimulated monocytes.  J Immunol 1998,
161:5681-5686.Page 8 of 8
(page number not for citation purposes)
